Patients who received Intercept Pharmaceuticals Incs experimental liverdisease drug in a clinical trial experienced more abnormal cholesterol levels than those taking a placebo in addition to improvements in their liver health according to the National Institutes of Health Patients taking the drug had disproportionate lipid abnormalitiesincluding worsened cholesterol levelscompared with patients who received a placebo in the person study according to the NIH The NIHs National Institute of Diabetes
  